A Study of Atezolizumab (TecentriqÂ®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.
Urothelial Carcinoma|Carcinoma, Non-Small Cell Lung|Small Cell Lung Carcinoma|Triple Negative Breast Carcinoma|Hepatocellular Carcinoma
DRUG: Atezolizumab
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs), Approximately 6 years
Percentage of Participants With Complete Response (CR) Assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Approximately 6 years|Percentage of Participants With Partial Response (PR) Assessed per RECIST 1.1, Approximately 6 years|Percentage of Participants With Stable Disease (SD) Assessed per RECIST 1.1, Approximately 6 years|Percentage of Participants With Progressive Disease (PD) Assessed per RECIST 1.1, Approximately 6 years
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.